Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Chikungunya: What Every Rheumatologist Needs to Know

Dany V. Thekkemuriyil, MD  |  Issue: November 2014  |  November 2, 2014

In the past several years, Chikungunya has emerged as a dangerous, rapidly spreading viral illness characterized mainly by debilitating arthritic symptoms. Chikungunya virus (CHIKV) is a single-stranded RNA virus of the genus Alphavirus. The virus is transmitted to humans by mosquitoes. The virus was first isolated from the serum of a febrile patient during an outbreak that occurred in the southern province of Tanzania (Makonde Plateau) in 1952–1953.1,2 The name Chikungunya translates in the Bantu language of the Makonde people to “that which bends up,” in reference to the stooped posture patients frequently adopt due to the frequent and incapacitating associated joint pain. Although initially limited to tropical Africa, South East Asia and the Indian Ocean islands, Chikungunya has spread to Europe and also, recently, to the American continents.3,4

Unlike most other viruses, CHIKV predominantly attacks the joint, and patients present with features similar to inflammatory arthritis. A period of persistent joint symptoms often follows the acute febrile phase, which is indeed difficult to distinguish from rheumatoid arthritis. Many of these cases get referred to rheumatologists, and thus, it’s important to create awareness about arthritis caused by CHIKV. This article describes the risk associated with the spread of this infection and clinical features, mainly focusing on rheumatic manifestations.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

How Far Has This Viral Infection Spread?

Although there have been reports of epidemics with fevers and predominant arthritis symptoms in the early 19th century, they were thought to be dengue fever. But it’s now felt they would better fit the presentation of Chikungunya infection.5 Since 1952, Chikungunya has been frequently reported in the African continent, and the first reported outbreak in Asia was in Thailand in 1958. Since then, a number of cases were reported from 1960 to 2000 in Africa and Asia.6,7

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Thekkemuriyil
Dr. Thekkemuriyil

But it was in 2005 when this viral outbreak caught global attention with the rapid spread of devastating outbreaks in the Indian Ocean islands. It was most notable in the Reunion Islands, affecting around 266,000 individuals (34% of the island’s population) and 75% of the population of Lamu (an island off the coast of Kenya).8,9 The French Territories in the Indian Ocean had more extensive administrative and technological resources than other islands in the region, so they had better local epidemic-monitoring systems. In India, nearly 1.4 million suspected cases of Chikungunya were reported in 2006.10,11

Although considered a tropical disease, an outbreak of Chikungunya occurred in northeastern Italy in 2007, resulting in more than 200 locally acquired cases.12 The index case was a traveler returning to Europe from India. Phylogenetic analysis of the virus demonstrated similarity with the Chikungunya strain found in the Indian Ocean outbreaks. This is an example for seasonal synchrony in which the period of active transmission in India coincided with Italy’s hottest months. It shortened the extrinsic incubation period, resulting in the early transmission of the virus to a new host.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Education & TrainingProfessional Topics Tagged with:chikungunyapatient carerheumatologistSafetySteroidssymptomTreatment

Related Articles

    Mosquito-Borne Chikungunya Virus Can Cause Long-Term Arthritis

    September 20, 2018

    Chikungunya is among a group of 16 diseases transmitted through mosquito, tick or flea bites that is of increasing public health concern in the U.S. Although few rheumatologists are likely to diagnose patients with the acute phase of the disease, they may encounter a handful of patients each year who complain of persistent, and often…

    Chikungunya Virus May Lead to Long-Term Joint Pain

    November 18, 2020

    COVID-19 isn’t the only viral infection on the rise across the globe, so is chikungunya, which can cause arthritis-like symptoms and may lead to long-term joint pain.

    Chikungunya Virus Vaccine Shows Promise in Early Clinical Trial

    April 21, 2020

    NEW YORK (Reuters Health)—A new chikungunya virus-like-particle vaccine appears to be safe and immunogenic, according to results from a phase 2 trial. “The phase 2 safety, tolerability and immunogenicity were similar to the data seen in an earlier phase 1 study,” Grace L. Chen, MD, of the National Institutes of Health Vaccine Research Center, Bethesda,…

    Experimental Drug Combination Curbs Chikungunya Arthritis in Mice

    May 16, 2017

    Doctors have had few options to treat the chronic rheumatoid arthritis-like symptoms associated with chikungunya virus infections beyond over-the-counter pain relievers. A recent study in Science Translational Medicine has spurred new optimism by finding that a combination therapy—the anti-rheumatic drug abatacept paired with a chikungunya-neutralizing monoclonal antibody—abolished acute symptoms in infected mice.1 The strategy must…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences